Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals Inc (ELDN) Historical Volatility
ELDN's 30 day historical volatility is 97.98%, in the 90th percentile of readings over the past year. This is a high percentile, meaning Eledon Pharmaceuticals Inc shares have swung far more than usual. ELDN's 30 day implied volatility sits at 192.18%, with an IV Rank of 75.00%, leaving IV 94.20 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.
Read more
Tracking ELDN historical volatility helps you see how much Eledon Pharmaceuticals Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ELDN's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ELDN 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ELDN's 30 day historical volatility, or ELDN HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ELDN's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 13, 2026
As of Nov 13, 2026
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →